Acorda Therapeutics (ACOR)
Acorda Therapeutics PEG Ratio: 0.0722
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ACOR PEG Ratio Rankings
| Overall | 85th percentile | 241 of 1713 |
| Sector | 88th percentile | 14 of 124 in Healthcare |
| Industry | 73rd percentile | 5 of 19 in Biotechnology |
ACOR PEG Ratio Range, Past 5 Years
| Minimum | 0.0722 | May 25 2012 |
| Maximum | 0.0851 | Mar 2012 |
| Average | 0.0786 |
About PEG Ratio
Click the "Learn More" link below to see how YCharts calculates the PEG Ratio.
The PEG ratio (Price/Earnings To Growth ratio) illustrates the relationship between stock price, earning per share, and the company's expected growth rate. The PEG ratio consists of the PE ratio divided by the company's growth rate. Using just the PE ratio makes high-growth companies look overvalued relative to others. By dividing the PE ratio by the earnings growth rate, the PEG ratio allows investors to accurately compare companies with different PE ratios and growth rates.
A company with a PEG ratio below 1 is considered undervalued. A company with a PEG ratio around 1 is considered fairly valued. A company with a PEG ratio greater than 1 is considered overvalued.
Learn More
You may also be interested in these ACOR related companies
ACOR News
Pre-Open Movers 5/18: (PSUN) (WGO) (CRM) Higher; (ADSK) (SQNM) (ARUN) Lower (more...)
May 18, 9:28AM Street Insider
May 18, 9:28AM Street Insider
News related to $ACOR, currently -1.1% since open: 'Alkermes takes bigger 4Q loss after Elan deal' http://stks.co/3sPL
about 10 days ago by TradeBot
about 10 days ago by TradeBot
2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.
May 17, 9:00AM Marketwire
May 17, 9:00AM Marketwire
Listen to $ACOR Q1 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3e2R
about 24 days ago by earningscast
about 24 days ago by earningscast
Acorda Therapeutics Recognized as One of the Best Places to Work in New York State for Second Consecutive Year
Apr 30, 7:00AM Business Wire
Apr 30, 7:00AM Business Wire
Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2012 Financial Results on May 3, 2012
Apr 26, 6:00AM Business Wire
Apr 26, 6:00AM Business Wire
Listen to $ACOR Acorda Therapeutics, Inc. Research & Development Conf Call - live at 10:00 AM, ondemand after - http://stks.co/3NSr
about 40 days ago by earningscast
about 40 days ago by earningscast
Acorda Therapeutics Named One of the 100 Most Trustworthy Companies by Forbes
Apr 12, 7:00AM Business Wire
Apr 12, 7:00AM Business Wire
$ACOR my biotech stock is back!!!! What happened here up another buck!
about 72 days ago by HTB_Krull
about 72 days ago by HTB_Krull
Acorda Therapeutics to Present at the Cowen & Company 32nd Annual Health Care Conference
Feb 27, 7:30AM Business Wire
Feb 27, 7:30AM Business Wire
Acorda Therapeutics to Present at 2012 RBC Capital Markets' Global Healthcare Conference
Feb 22, 6:00AM Business Wire
Feb 22, 6:00AM Business Wire
Acorda Therapeutics to Present at Citi 2012 Global Health Care Conference
Feb 21, 6:00AM Business Wire
Feb 21, 6:00AM Business Wire
Citi Downgrades Acorda Therapeutics, Inc. (ACOR) to Neutral, Raises Price Target to $29
Feb 17, 7:36AM Street Insider
Feb 17, 7:36AM Street Insider
Big earnings beat for $acor, but the market is not too excited yet. It has 6 days of short interest, so it is one to watch if it gets going
about 101 days ago by ivanhoff
about 101 days ago by ivanhoff
Listen to $ACOR Q4 2011 earnings call (EPS 0.45 vs est 0.18) - live at 08:30 AM, ondemand after - http://stks.co/2RDb
about 101 days ago by earningscast
about 101 days ago by earningscast
Listen to $ACOR Acorda Therapeutics, Inc. at Biotechnology Industry Organization - live at 01:00 PM, ondemand after - http://stks.co/2Opp
about 103 days ago by earningscast
about 103 days ago by earningscast
$ACOR may be flashing pocket pivot today as it rebounds from its 50-day line in above average volume. Strong fundamentals. Good accumulation
about 104 days ago by JeanPaul
about 104 days ago by JeanPaul
BIO CEO Conference Live Blog. http://stks.co/2N3g $ONTY $KERX $GILD $CYCC $IDIX $CHTP $ACOR
about 104 days ago by abubnic
about 104 days ago by abubnic
$REGN is one just started shorting since hitting near $102 mon, little scalps have netted a few pts , has ER next wk with $ACOR & $NPSP
about 109 days ago by ronin245
about 109 days ago by ronin245
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACOR | 22.54 | -0.12 | -0.53% | 894.84M |
| ACOM | 21.88 | +0.09 | +0.41% | 937.78M |
| ACO | 29.03 | -0.83 | -2.78% | 924.90M |
| ACN | 57.44 | -0.55 | -0.95% | 37.18B |
| ACM | 16.69 | +0.06 | +0.36% | 1.955B |
| ACLS | 1.12 | +0.11 | +10.89% | 120.00M |
| ACIW | 40.03 | -0.07 | -0.17% | 1.568B |
| ACI | 7.23 | -0.07 | -0.96% | 1.533B |
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ABB | 16.18 | -0.22 | -1.34% | 37.45B |
